Showing 7581-7590 of 8546 results for "".
- ASLMS Announces Dr. Horace Furumoto Award Recipientshttps://practicaldermatology.com/news/20131126-laser_society_announces_dr_horace_furumoto_award_recipients/2459402/Michael H. Slayton, Ph.D. and Ishan Barman, Ph.D. will receive the Horace Furumoto Innovations Professional Development Awards at the upcoming meeting of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), which will be held in April 2014, in Phoenix, AZ. Dr. Thomas Rohrer, Chair of the
- Caliber Imaging & Diagnostics Appoints Robert P. Fischmann VP of Operationshttps://practicaldermatology.com/news/20131125-caliber_imaging__diagnostics_appoints_robert_p_fischmann_vp_of_operations/2459406/Caliber Imaging & Diagnostics, formerly Lucid, Inc., has appointed Robert P. Fischmann to the role of Vice President of Operations, a newly created position. Mr. Fischmann's responsibilities at
- Signum Dermalogix Receives Grant for the Development of Atopic Dermatitis Therapeuticshttps://practicaldermatology.com/news/20131114-signum_dermalogix_receives_grant_for_the_development_of_atopic_dermatitis_therapeutics/2459415/The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Signum Dermalogix, Inc. (Dermalogix) a Small Business Innovat
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Data Indicate Need to Critically Assess Sunscreen Formulationshttps://practicaldermatology.com/news/20131107-data_indicate_need_to_critically_assess_sunscreen_formulations/2459419/When it comes to sunscreen selection, consumers may benefit from an assessment of a product's specific formulation rather than simply a “Broad Spectrum” claim, according to a poster presented at last month's Fall Clinical Dermatology Conference (Ouyang, et al.). The poster analyzed the critical wave
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P